Literature DB >> 20237297

Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice.

Maria de la Luz Garcia-Hernandez1, Hiromasa Hamada, Joyce B Reome, Sara K Misra, Michael P Tighe, Richard W Dutton.   

Abstract

In vitro generated OVA-specific IL-17-producing CD8 T effector cells (Tc17) from OT-1 mice, adoptively transferred into B16-OVA tumor-bearing mice, controlled tumor growth in early and late stage melanoma. IL-17, TNF, and IFN-gamma from the Tc17 effectors all played a role in an enhanced recruitment of T cells, neutrophils, and macrophages to the tumor. In addition, Tc17 cells and recently recruited, activated neutrophils produced further chemokines, including CCL3, CCL4, CCL5, CXCL9, and CXCL10, responsible for the attraction of type 1 lymphocytes (Th1 and Tc1) and additional neutrophils. Neutrophils were rapidly attracted to the tumor site by an IL-17 dependent mechanism, but at later stages the induction of the chemokine CXCL2 by Tc17-derived TNF and IFN-gamma contributed to sustain neutrophil recruitment. Approximately 10-50 times as many Tc17 effectors were required compared with Tc1 effectors to exert the same level of control over tumor growth. The recruitment of neutrophils was more prominent when Tc17 rather than Tc1 were used to control tumor and depletion of neutrophils resulted in a diminished capacity to control tumor growth.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237297      PMCID: PMC2851479          DOI: 10.4049/jimmunol.0902995

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.

Authors:  M J Dobrzanski; J B Reome; R W Dutton
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

2.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

3.  The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.

Authors:  B K Helmich; R W Dutton
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

4.  Interleukin-17 promotes angiogenesis and tumor growth.

Authors:  Muneo Numasaki; Jun-ichi Fukushi; Mayumi Ono; Satwant K Narula; Paul J Zavodny; Toshio Kudo; Paul D Robbins; Hideaki Tahara; Michael T Lotze
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

5.  Requirement of endogenous stem cell factor and granulocyte-colony-stimulating factor for IL-17-mediated granulopoiesis.

Authors:  P Schwarzenberger; W Huang; P Ye; P Oliver; M Manuel; Z Zhang; G Bagby; S Nelson; J K Kolls
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

6.  Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice.

Authors:  N Hirahara; Y Nio; S Sasaki; Y Minari; M Takamura; C Iguchi; M Dong; K Yamasawa; K Tamura
Journal:  Oncology       Date:  2001       Impact factor: 2.935

7.  Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism.

Authors:  Fabrice Benchetrit; Arnaud Ciree; Virginie Vives; Guy Warnier; Alain Gey; Catherine Sautès-Fridman; François Fossiez; Nacilla Haicheur; Wolf H Fridman; Eric Tartour
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

8.  Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation.

Authors:  M L García-Hernández; R Hernández-Pando; P Gariglio; Jaime Berumen
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

9.  Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis.

Authors:  Yoshinaga Ito; Takashi Usui; Shio Kobayashi; Mikiko Iguchi-Hashimoto; Hiromu Ito; Hiroyuki Yoshitomi; Takashi Nakamura; Masakazu Shimizu; Daisuke Kawabata; Naoichiro Yukawa; Motomu Hashimoto; Noriko Sakaguchi; Shimon Sakaguchi; Hajime Yoshifuji; Takaki Nojima; Koichiro Ohmura; Takao Fujii; Tsuneyo Mimori
Journal:  Arthritis Rheum       Date:  2009-08

10.  The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.

Authors:  Sheila A Caldwell; Mary H Ryan; Elwood McDuffie; Scott I Abrams
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

View more
  51 in total

Review 1.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

2.  Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.

Authors:  Jacob S Bowers; Michelle H Nelson; Sreenath Kundimi; Stefanie R Bailey; Logan W Huff; Kristina M Schwartz; David J Cole; Mark P Rubinstein; Chrystal M Paulos
Journal:  Clin Cancer Res       Date:  2015-04-22       Impact factor: 12.531

3.  The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs.

Authors:  Aditya Arra; Holger Lingel; Benno Kuropka; Jonas Pick; Tina Schnoeder; Thomas Fischer; Christian Freund; Mandy Pierau; Monika C Brunner-Weinzierl
Journal:  Oncoimmunology       Date:  2017-01-20       Impact factor: 8.110

4.  Pleural mesothelial cells promote expansion of IL-17-producing CD8+ T cells in tuberculous pleural effusion.

Authors:  X Li; Q Zhou; W B Yang; X Z Xiong; R H Du; J C Zhang
Journal:  J Clin Immunol       Date:  2013-01-09       Impact factor: 8.317

5.  Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape.

Authors:  Karen M Kaluza; Timothy Kottke; Rosa Maria Diaz; Diana Rommelfanger; Jill Thompson; Richard Vile
Journal:  Hum Gene Ther       Date:  2012-08-13       Impact factor: 5.695

6.  Effect of chronic morphine administration on circulating T cell population dynamics in rhesus macaques.

Authors:  William D Cornwell; Mark G Lewis; Xiaoxuan Fan; Jay Rappaport; Thomas J Rogers
Journal:  J Neuroimmunol       Date:  2013-09-20       Impact factor: 3.478

7.  Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers.

Authors:  Yong Lu; Bangxing Hong; Haiyan Li; Yuhuan Zheng; Mingjun Zhang; Siqing Wang; Jianfei Qian; Qing Yi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

8.  Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development.

Authors:  R Kesselring; A Thiel; R Pries; T Trenkle; B Wollenberg
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

9.  Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.

Authors:  Yu Yu; Hyun-Ii Cho; Dapeng Wang; Kane Kaosaard; Claudio Anasetti; Esteban Celis; Xue-Zhong Yu
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

10.  Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression.

Authors:  Ainhoa Arina; Karin Schreiber; David C Binder; Theodore G Karrison; Rebecca B Liu; Hans Schreiber
Journal:  J Immunol       Date:  2013-12-23       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.